From the USA: ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma

For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) yields durable remission, according to a study published in the June 20 issue of the New England Journal of Medicine.

Christopher Melani, M.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues performed a single-center, phase 1b to 2 study of a regimen of ViPOR in relapsed or refractory DLBCL. Twenty patients were included in phase 1b, 10 with DLBCL, which assessed four dose levels of venetoclax. A phase 2 expansion was conducted in 40 patients with germinal-center B-cell (GCB) and non-GCB DLBCL.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=MGY5MzZkY2QtMmRkYy00MjRiLWEyZGUtOTQ3MjI1ZjUwZWY3&client=Nw%3D%3D&section=undefined